Dataset Information

Impact of Tobacco Smoking on the risk of COVID-19.A large scale retrospective cohort study.

ABSTRACT:

Introduction

Preliminary reports indicated that smokers could be less susceptible to the coronavirus SARS-CoV-2, which causes Covid-19. However, once infected an increased risk of severe disease is reported. We investigated the association between smoking and COVID-19 during an outbreak of the disease on a naval vessel.

Methods

We conducted a cross-sectional, observational study on the 1769 sailors of a same navy aircraft carrier at sea exposed at the same time to SARS-CoV2 to investigate the link between tobacco consumption and Covid-19.

Results

Among the 1688 crewmembers (87% men; median age= 28 (IQR 23-35)) included, 1279 (76%) developed Covid-19 (1038 (62%) RT-PCR-positive and 241 (14%) with only clinical signs). One hundred and seven patients were hospitalized. The univariable analysis odds ratio (OR) for Covid-19 infection was 0.59 (95% confidence interval (CI), 0.45-0.78; P<0.001) for current smokers vs. former and nonsmokers; sex, body mass index or blood group had no significant impact. Crewmembers >50 years old had an increased risk of contracting Covid-19 (OR, 2.84 [95% CI, 1.30-7.5]; P=0.01). Multivariable analysis retained the lower risk of current smokers becoming infected (OR, 0.64 [0.49-0.84]; P<0.001) and age >50 years was significatively associated with Covid-19 (OR, 2.6 [1.17-6.9]; P=0.03).

Conclusions

Current smoking status was associated with a lower risk of developing Covid-19 but cannot be considered as an efficient protection against infection. Mechanism of the lower susceptibility of smokers to SARS-CoV-2 requires further research.

Implications

Recent epidemiologic data suggest a paradoxical link between smoking and Covid-19. Among the 1688 crewmembers (with an attack rate of 76% and exposed at the same time in the same place to SARS-CoV2), we found a significant lower risk for developing COVID-19 in current smokers (71%) versus former and non smokers (80%). This finding strongly supports the need for further research on nicotine physiological pathway and its impact on COVID-19 infection whilst emphasizing that tobacco smoking should not be considered as an efficient protection against COVID-19.

SUBMITTER: Paleiron N

PROVIDER: S-EPMC7953961 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Impact of Tobacco Smoking on the Risk of COVID-19: A Large Scale Retrospective Cohort Study.

Paleiron Nicolas N Mayet Aurélie A Marbac Vanessa V Perisse Anne A Barazzutti Hélène H Brocq François-Xavier FX Janvier Frédéric F Dautzenberg Bertrand B Bylicki Olivier O

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 20210801 8

<h4>Introduction</h4>Preliminary reports indicated that smokers could be less susceptible to coronavirus SARS-CoV-2, which causes Covid-19. However, once infected an increased risk of severe disease is reported. We investigated the association between smoking and COVID-19 during an outbreak of the disease on a naval vessel.<h4>Methods</h4>We conducted a cross-sectional, observational study on the 1769 sailors of the same navy aircraft carrier at sea exposed at the same time to SARS-CoV2 to inves ...[more]

PMID: 33420786

Similar Datasets

Project description:Using RNA-seq and high-resolution mass spectrometry we performed a comprehensive systems analysis on 128 plasma and leukocyte samples from hospitalized patients with or without COVID-19 (n=102 and 26 respectively) and with differing degrees of disease severity. We generated abundance measurements for over 17,000 transcripts, proteins, metabolites, and lipids and compiled them with clinical data into a curated relational database. This resource offers the unique opportunity to perform systems analysis and cross-ome correlations to both molecules and patient outcomes. In total 219 molecular features were mapped with high significance to COVID-19 status and severity, including those involved in processes such as complement system activation, dysregulated lipid transport, and B cell activation. In one example, we detected a trio of covarying molecules – citrate, plasmenyl-phosphatidylcholines, and gelsolin (GSN) – that offer both pathophysiological insight and potential novel therapeutic targets. Further, our data revealed in some cases, and supported in others, that several biological processes were dysregulated in COVID-19 patients including vessel damage, platelet activation and degranulation, blood coagulation, and acute phase response. For example, we observed that the coagulation-related protein, cellular fibronectin (cFN), was highly increased within COVID-19 patients and provide new evidence that the upregulated proteoform stems from endothelial cells, consistent with endothelial injury as a major activator of the coagulation cascade. The abundance of prothrombin, which is cleaved to form thrombin during clotting, was significantly reduced and correlated with severity and might help to explain the hyper coagulative environment of SARS-CoV-2 infection. From transcriptomic analysis of leukocytes, we concluded that COVID-19 patients with acute respiratory distress syndrome (ARDS) demonstrated a phenotype that overlapped with, but was distinct from, that found in patients with non-COVID-19-ARDS. To aid in the global efforts toward elucidation of disease pathophysiology and therapeutic development, we created a web-based tool with interactive visualizations allowing for easy navigation of this systems-level compendium of biomolecule abundance in relation to COVID-19 status and severity. Finally, we leveraged these multi-omic data to predict COVID-19 patient outcomes with machine learning, which highlighted the predictive power of these expansive molecular measurements beyond the standardized clinical estimate of 10-year survival Charlson score.